Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation

Nature Neuroscience volume 24, pages 1100–1109 (2021)Cite this article

Subjects

Abstract

The rapidly acting antidepressants ketamine and scopolamine exert behavioral effects that can last from several days to more than a week in some patients. The molecular mechanisms underlying the maintenance of these antidepressant effects are unknown. Here we show that methyl-CpG-binding protein 2 (MeCP2) phosphorylation at Ser421 (pMeCP2) is essential for the sustained, but not the rapid, antidepressant effects of ketamine and scopolamine in mice. Our results reveal that pMeCP2 is downstream of BDNF, a critical factor in ketamine and scopolamine antidepressant action. In addition, we show that pMeCP2 is required for the long-term regulation of synaptic strength after ketamine or scopolamine administration. These results demonstrate that pMeCP2 and associated synaptic plasticity are essential determinants of sustained antidepressant effects.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: BDNF-dependent pMeCP2 is essential for sustained antidepressant response of ketamine.
Fig. 2: CREB and MEF2C are not involved in the sustained effects of ketamine.
Fig. 3: pMeCP2 is essential for ketamine-induced metaplasticity in SC–CA1 synapses.
Fig. 4: BDNF-dependent pMeCP2 mediates the sustained antidepressant response of scopolamine.
Fig. 5: Phospho-MeCP2 is essential for sustained changes in pre-synaptic release probability by scopolamine.
Fig. 6: Pirenzepine upregulates MeCP2 phosphorylation and increases release probability.
Fig. 7: Sustained antidepressant effects of ketamine and scopolamine in a corticosterone-induced animal model of depression.

Data availability

The raw data that support the findings of the current study are available from the corresponding author upon reasonable request. Source data are provided with this paper.

References

  1. Quitkin, F. M. et al. Use of pattern analysis to identify true drug response. A replication. Arch. Gen. Psychiatry 44, 259–264 (1987).

    Article  CAS  PubMed  Google Scholar 

  2. Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351–354 (2000).

    Article  CAS  PubMed  Google Scholar 

  3. Zarate, C. A. Jr. et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864 (2006).

    Article  CAS  PubMed  Google Scholar 

  4. Furey, M. L. & Drevets, W. C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 63, 1121–1129 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Drevets, W. C. & Furey, M. L. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry 67, 432–438 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91–95 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Beurel, E., Song, L. & Jope, R. S. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol. Psychiatry 16, 1068–1070 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nosyreva, E. et al. Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J. Neurosci. 33, 6990–7002 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T. & Monteggia, L. M. Effects of a ketamine metabolite on synaptic NMDAR function. Nature 546, E1–E3 (2017).

    Article  CAS  PubMed  Google Scholar 

  11. Ghosal, S. et al. Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine. Biol. Psychiatry 83, 29–37 (2018).

    Article  CAS  PubMed  Google Scholar 

  12. Monteggia, L. M. & Kavalali, E. T. Scopolamine and ketamine: evidence of convergence? Biol. Psychiatry 74, 712–713 (2013).

    Article  CAS  PubMed  Google Scholar 

  13. Voleti, B. et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol. Psychiatry 74, 742–749 (2013).

    Article  CAS  PubMed  Google Scholar 

  14. Alberini, C. M. Transcription factors in long-term memory and synaptic plasticity. Physiol. Rev. 89, 121–145 (2009).

    Article  CAS  PubMed  Google Scholar 

  15. Nan, X., Campoy, F. J. & Bird, A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88, 471–481 (1997).

    Article  CAS  PubMed  Google Scholar 

  16. Guy, J., Cheval, H., Selfridge, J. & Bird, A. The role of MeCP2 in the brain. Annu. Rev. Cell Dev. Biol. 27, 631–652 (2011).

    Article  CAS  PubMed  Google Scholar 

  17. Zhou, Z. et al. Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturation. Neuron 52, 255–269 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sheng, M., Thompson, M. A. & Greenberg, M. E. CREB: a Ca2+-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science 252, 1427–1430 (1991).

    Article  CAS  PubMed  Google Scholar 

  19. Tao, X., Finkbeiner, S., Arnold, D. B., Shaywitz, A. J. & Greenberg, M. E. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20, 709–726 (1998).

    Article  CAS  PubMed  Google Scholar 

  20. Bourtchuladze, R. et al. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell 79, 59–68 (1994).

    Article  CAS  PubMed  Google Scholar 

  21. Finkbeiner, S. et al. CREB: a major mediator of neuronal neurotrophin responses. Neuron 19, 1031–1047 (1997).

    Article  CAS  PubMed  Google Scholar 

  22. Barbosa, A. C. et al. MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function. Proc. Natl Acad. Sci. USA 105, 9391–9396 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Adachi, M., Lin, P. Y., Pranav, H. & Monteggia, L. M. Postnatal loss of Mef2c results in dissociation of effects on synapse number and learning and memory. Biol. Psychiatry 80, 140–148 (2016).

    Article  CAS  PubMed  Google Scholar 

  24. Maeng, S. et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349–352 (2008).

    Article  CAS  PubMed  Google Scholar 

  25. Moda-Sava, R. N. et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 364, eaat8078 (2019).

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Zanos, P. et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533, 481–486 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Cohen, S. et al. Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and function. Neuron 72, 72–85 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Monteggia, L. M. et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl Acad. Sci. USA 101, 10827–10832 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kim, J. W. & Monteggia, L. M. Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways. Behav. Brain Res. 380, 112378 (2020).

    Article  CAS  PubMed  Google Scholar 

  30. Zhang, K. et al. Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine. Sci. Signal. 9, ra123 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. aan het Rot, M. et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol. Psychiatry 67, 139–145 (2010).

    Article  CAS  PubMed  Google Scholar 

  32. Murrough, J. W. et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry 74, 250–256 (2013).

    Article  CAS  PubMed  Google Scholar 

  33. Phillips, J. L. et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am. J. Psychiatry 176, 401–409 (2019).

    Article  PubMed  Google Scholar 

  34. Buchthal, B., Lau, D., Weiss, U., Weislogel, J. M. & Bading, H. Nuclear calcium signaling controls methyl-CpG-binding protein 2 (MeCP2) phosphorylation on serine 421 following synaptic activity. J. Biol. Chem. 287, 30967–30974 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Bayer, K. U. & Schulman, H. CaM kinase: still inspiring at 40. Neuron 103, 380–394 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Tobimatsu, T. & Fujisawa, H. Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs. J. Biol. Chem. 264, 17907–17912 (1989).

    Article  CAS  PubMed  Google Scholar 

  37. Egan, M. F. et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112, 257–269 (2003).

    Article  CAS  PubMed  Google Scholar 

  38. Scheiderer, C. L. et al. Sympathetic sprouting drives hippocampal cholinergic reinnervation that prevents loss of a muscarinic receptor-dependent long-term depression at CA3–CA1 synapses. J. Neurosci. 26, 3745–3756 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mans, R. A., Warmus, B. A., Smith, C. C. & McMahon, L. L. An acetylcholinesterase inhibitor, eserine, induces long-term depression at CA3–CA1 synapses in the hippocampus of adult rats. J. Neurophysiol. 112, 2388–2397 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Holderbach, R., Clark, K., Moreau, J. L., Bischofberger, J. & Normann, C. Enhanced long-term synaptic depression in an animal model of depression. Biol. Psychiatry 62, 92–100 (2007).

    Article  PubMed  Google Scholar 

  41. Mineur, Y. S. et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc. Natl Acad. Sci. USA 110, 3573–3578 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Navarria, A. et al. Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol. Dis. 82, 254–261 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Gourley, S. L. & Taylor, J. R. Recapitulation and reversal of a persistent depression-like syndrome in rodents. Curr. Protoc. Neurosci. 49, 9.32.1–9.32.11 (2009).

    Article  Google Scholar 

  44. Hutchinson, A. N., Deng, J. V., Cohen, S. & West, A. E. Phosphorylation of MeCP2 at Ser421 contributes to chronic antidepressant action. J. Neurosci. 32, 14355–14363 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Skene, P. J. et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol. Cell 37, 457–468 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Chen, W. G. et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302, 885–889 (2003).

    Article  CAS  PubMed  Google Scholar 

  47. Brocke, L., Chiang, L. W., Wagner, P. D. & Schulman, H. Functional implications of the subunit composition of neuronal CaM kinase II. J. Biol. Chem. 274, 22713–22722 (1999).

    Article  CAS  PubMed  Google Scholar 

  48. Adaikkan, C., Taha, E., Barrera, I., David, O. & Rosenblum, K. Calcium/calmodulin-dependent protein kinase II and eukaryotic elongation factor 2 kinase pathways mediate the antidepressant action of ketamine. Biol. Psychiatry 84, 65–75 (2018).

    Article  CAS  PubMed  Google Scholar 

  49. Carreno, F. R. et al. Activation of a ventral hippocampus-medial prefrontal cortex pathway is both necessary and sufficient for an antidepressant response to ketamine. Mol. Psychiatry 21, 1298–1308 (2016).

    Article  CAS  PubMed  Google Scholar 

  50. Dulawa, S. C. & Janowsky, D. S. Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Mol. Psychiatry 24, 694–709 (2019).

    Article  CAS  PubMed  Google Scholar 

  51. Chen, J. et al. Transgenic animals with inducible, targeted gene expression in brain. Mol. Pharmacol. 54, 495–503 (1998).

    Article  CAS  PubMed  Google Scholar 

  52. Hill, J. J. et al. Analysis of pyramidal neuron morphology in an inducible knockout of brain-derived neurotrophic factor. Biol. Psychiatry 57, 932–934 (2005).

    Article  CAS  PubMed  Google Scholar 

  53. Deng, J. V. et al. MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. Nat. Neurosci. 13, 1128–1136 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank members of the Monteggia and Kavalali laboratory for helpful advice and discussions on the manuscript. We thank K. Szabla for the initial insight into this project. We thank A. West for providing the initial pMeCP2 antibody for these studies. This work was supported by National Institutes of Health grants MH070727 and MH081060 (to L.M.M.) and MH066198 (to E.T.K.); the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Education (2016R1A6A3A03008533, to J.K.); and postdoctoral fellowships from the Elisabeth and Alfred Ahlqvist Foundation within the Swedish Pharmaceutical Society and the Swedish Society for Medical Research (to C.B.).

Author information

Authors and Affiliations

  1. Department of Pharmacology, School of Medicine, Vanderbilt University, Nashville, TN, USA

    Ji-Woon Kim, Ege T. Kavalali & Lisa M. Monteggia

  2. Department of Neuroscience, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ji-Woon Kim, Anita E. Autry, Elisa S. Na, Megumi Adachi, Carl Björkholm, Ege T. Kavalali & Lisa M. Monteggia

Authors
  1. Ji-Woon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anita E. Autry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisa S. Na
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Megumi Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carl Björkholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ege T. Kavalali
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lisa M. Monteggia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

J.K., A.E.A. and M.A. performed behavioral tests. J.K. and E.S.N. conducted electrophysiology experiments. J.K., A.E.A. and C.B. performed biochemistry experiments. L.M.M., E.T.K. and J.K. designed experiments and wrote the manuscript.

Corresponding author

Correspondence to Lisa M. Monteggia.

Ethics declarations

Competing interests

C.B. is currently employed by Janssen-Cilag AB, Sweden, but contributed to this work in his previous position at UTSW. Janssen-Cilag AB had no part in the planning, execution or funding of this study. The other authors declare no competing financial interests.

Additional information

Peer review information Nature Neuroscience thanks the anonymous reviewers for their contribution to the peer review of this work.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 pMeCP2 is not changed in the medial prefrontal cortex 7 days after ketamine treatment.

pMeCP2 levels were measured with Western blot analysis in the medial prefrontal cortex of C57BL/6J mice 7 days after ketamine treatment. No significant changes in pMeCP2 levels were observed between saline- and ketamine-treated groups. (two-sided unpaired t-test, ketamine: t(14) = 0.3298, P = 0.7464, n = 8 mice per group). In Western blot analysis for pMeCP2, membrane above about 70 KDa was cropped and used for immunoblotting. The graph represents mean ± S.E.M., N.S.: not significant, Sal: saline, Ket: ketamine. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 2 Ketamine rapidly increases BDNF protein levels in the hippocampus of Mecp2 S421A KI mice.

BDNF protein levels were measured 30 min after ketamine treatment in Mecp2 KI and CTL mice by Western blot analysis. BDNF levels were significantly increased by ketamine treatment in both the CTL and KI mice (two-way ANOVA with Tukey’s multiple comparisons, Genotype x Drug: F(1, 21) = 0.0157, P = 0.9016, Genotype: F(1, 21) = 0.0115, P = 0.9158, Drug: F(1, 21) = 31.93, P < 0.0001, CTL-Sal, CTL-Ket, KI-Sal, KI-Ket: n = 7, 7, 6, 5 mice). In Western blot analysis for pMeCP2, membrane above about 70 KDa was cropped and used for immunoblotting. The graph represents mean ± S.E.M., **, P < 0.01, Sal: saline, Ket: ketamine, CTL: littermate control. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 3 Effects of ketamine on pre-and post-synaptic function at 7 days after treatment.

a, Saline or ketamine was administered to C57BL/6J mice. The mice were sacrificed 7 days later, and slices were prepared for recordings. I-O curves were measured during baseline recording in the SC-CA1 synapses. I-O curves of Sal and Ket groups were from baseline recording in the Sal-Ket group of Fig. 3b and Ket-Ket group of Fig. 3c, respectively. The slope of I-O curves in the previous ketamine-treated group was not significantly different compared to the saline-treated group (two-sided unpaired t-test, t(17) = 1.448, P = 0.1659, Sal, Ket: n = 9, 10 slices). b, PPRs were measured before and after ketamine perfusion onto hippocampal slices of mice given either saline or ketamine 7 days before the slice preparation. PPRs were not significantly changed by either previous ketamine injection or subsequent ketamine perfusion (two-way ANOVA with Tukey’s multiple comparisons, all P-values > 0.05, Sal-Ket, Ket-Ket: n = 11, 10 slices). Representative traces are from data recorded at 30 msec interstimulus interval in the respective treatment groups. Graphs represent mean ± S.E.M., N.S.: not significant, Sal: saline, Ket: ketamine. Sal+Ket: ketamine perfusion onto hippocampal slices from saline-injected mice, Ket+Ket: ketamine perfusion onto hippocampal slices from ketamine-injected mice. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 4 Ketamine-induced metaplasticity is observed in female mice.

a,b, Ketamine-potentiation was measured in the Schaffer collateral to CA1 synapses of C57BL/6J female mice given either saline (a) or ketamine (b) injection 7 days before slice preparation. Augmented potentiation was observed in the group previously treated with ketamine (b: Ket+Ket, 138.5 ± 6.717%), compared to the group previously treated with saline (a: Sal+Ket, 114 ± 3.158%), (two-sided unpaired t-test, a - Sal+ACSF vs Sal+Ket: t(11) = 4.207, P = 0.0015, Sal+ACSF, Sal+Ket: n = 6, 7 slices, b - Ket+ACSF vs Ket+Ket: t(10) = 5.528, P = 0.0003, Ket+ACSF, Ket+Ket: n = 6, 6 slices, Sal+Ket in a vs Ket+Ket in b: t(11) = 3.465, P = 0.0053). Graphs represent mean ± S.E.M., **, P < 0.01, ***, P < 0.001, Sal: saline, Ket: ketamine. Sal+ACSF: ACSF perfusion onto hippocampal slices from saline-injected mice, Sal+Ket: ketamine perfusion onto hippocampal slices from saline-injected mice, Ket+ACSF: ACSF perfusion onto hippocampal slices from ketamine-injected mice, Ket+Ket: ketamine perfusion onto hippocampal slices from ketamine-injected mice. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 5 Molecular changes in the CA1 hippocampal region at 3 or 7 days after ketamine treatment.

a,b, The hippocampal CA1 area was collected in C57BL6/J mice 3 or 7 days after ketamine treatment. Phosphorylation of CaMKIIβ, but not CaMKIIα, was significantly increased by ketamine at 3 days compared to the saline group, and the increased phosphorylation returned to the levels of the saline-treated group at 7 days (two-sided unpaired t-test, 3 days, CaMKIIα: t(14) = 0.4369, P = 0.6688, CaMKIIβ: t(14) = 3.756, P = 0.0021, n = 8 mice per group, 7 days, CaMKIIα: t(14) = 1.052, P = 0.3107, CaMKIIβ: t(14) = 0.3796, P = 0.7100, n = 8 mice per group). pMeCP2 levels were significantly increased at both 3 and 7 days (two-sided unpaired t-test, 3 days: t(16) = 2.332, P = 0.0331, n = 9 mice per group, 7 days: t(14) = 2.440, P = 0.0286, n = 8 mice per group). BDNF levels were not changed at 3 days (two-sided unpaired t-test, t(14) = 0.0433, P = 0.9661, n = 8 mice per group). In Western blot analysis for pMeCP2, membrane above about 70 KDa was cropped and used for immunoblotting. Graphs represent mean ± S.E.M., N.S.: not significant, *, P < 0.05, **, P < 0.01, Sal: saline, Ket: ketamine. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 6 Effects of scopolamine at 7 days after injection.

a, Immobility was measured in the FST 7 days after scopolamine treatment. The scopolamine-treated group showed a significant reduction in time spent immobile compared to the saline-treated group (two-sided unpaired t-test, t(17) = 2.469, P = 0.0244, Sal, SCA: n = 9, 10 mice). b, PPRs were analyzed in the hippocampal CA1 area of C57BL/6J mice given scopolamine 7 days prior. The PPRs were significantly reduced in the scopolamine-treated group compared to the saline-treated group at 20 and 30 msec interstimulus interval condition (two-sided Mann-Whitney test, 20 msec: U = 210, P = 0.0314, 30 msec: U = 207, P = 0.0270, Sal, SCA: n = 24, 27 slices). Graphs represent mean ± S.E.M., N.S.: not significant, *, P < 0.05, Sal: saline, SCA: scopolamine. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 7 Actinomycin D prevents scopolamine-mediated sustained behavioral effects.

Actinomycin D was administered to C57BL/6J mice prior to the saline or scopolamine treatment, and the mice were tested 24 hrs later in the FST. Scopolamine did not significantly reduce the duration of immobility of the mice pretreated with actinomycin D (two-sided unpaired t-test, t(17) = 1.006, P = 0.3286, ActD-Sal, ActD-SCA : n = 10, 9 mice). The Graph represents mean ± S.E.M., N.S.: not significant, Sal: saline, SCA: scopolamine. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 8 pMeCP2 is not changed in the medial prefrontal cortex 24 hrs after scopolamine treatment.

pMeCP2 levels were measured in the medial prefrontal cortex of C57BL/6J mice 24 hrs after scopolamine treatment with Western blot analysis. No significant differences in pMeCP2 levels were observed between saline- and scopolamine-treated groups (two-sided unpaired t-test, t(14) = 0.0705, P = 0.9448, n = 8 mice per group). In Western blot analysis for pMeCP2, membrane above about 70 KDa was cropped and used for immunoblotting. The Graph represents mean ± S.E.M., N.S.: not significant, Sal: saline, SCA: scopolamine. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 9 Scopolamine does not affect CREB phosphorylation.

pCREB levels were measured in the hippocampus of C57BL/6J mice with Western blot analysis 8 hrs and 24 hrs after scopolamine treatment. No significant differences were observed between Sal- and SCA-treated groups at either time point (two-sided unpaired t-test or Welch’s correct t-test, 8 hrs: t(9.272) = 0.9004, P = 0.3907, n = 8 mice per group, 24 hrs: t(12) = 0.0677, P = 0.9472, n = 7 mice per group). The Graph represents mean ± S.E.M., N.S.: not significant, Sal: Saline, SCA: Scopolamine. For detailed statistical information, see Supplementary Table 1.

Extended Data Fig. 10 Scopolamine increases Bdnf mRNA levels in the hippocampus of Mecp2 S421A KI mice 8 hours after injection.

Bdnf mRNA levels were measured with quantitative real-time PCR in CTL and Mecp2 KI mice 8 hrs after scopolamine. Scopolamine treatment significantly increased Bdnf mRNA levels in the hippocampus of both the CTL and KI mice (two-way ANOVA with Tukey’s multiple comparisons, Genotype x Drug: F(1, 33) = 0.0467, P = 0.8302, Genotype: F(1, 33) = 0.3223, P = 0.5741, Drug: F(1, 33) = 19.22, P = 0.0001, CTL-Sal, CTL-SCA, KI-Sal, KI-SCA: n = 10, 9, 10, 8 mice). The Graph represents mean ± S.E.M., *, P < 0.05, Sal: saline, SCA: scopolamine, CTL: littermate control. For detailed statistical information, see Supplementary Table 1.

Supplementary information

Source data

Fig. 1

Unprocessed western blots.

Fig. 2

Unprocessed western blots.

Fig. 4

Unprocessed western blots.

Fig. 6

Unprocessed western blots.

Extended Data Fig. 1

Unprocessed western blots.

Extended Data Fig. 2

Unprocessed western blots.

Extended Data Fig. 5

Unprocessed western blots.

Extended Data Fig. 8

Unprocessed western blots.

Extended Data Fig. 9

Unprocessed western blots.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, JW., Autry, A.E., Na, E.S. et al. Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation. Nat Neurosci 24, 1100–1109 (2021). https://doi.org/10.1038/s41593-021-00868-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41593-021-00868-8

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing